Quarterly ResultMay 8, 2026, 07:06 AM
Treace Medical Q1 Revenue $47.2M, Net Loss $(18.0)M
AI Summary
Treace Medical Concepts reported its first quarter 2026 financial results, with revenue decreasing 10% year-over-year to $47.2 million and net loss widening to $(18.0) million. Adjusted EBITDA also saw a larger loss of $(5.5) million. Despite the financial declines, the company increased its cash, cash equivalents, and marketable securities to $51.9 million and initiated the limited market release of its SuperBite Compression Screw System. Treace Medical reaffirmed its full-year 2026 revenue guidance and expects a reduction in cash usage by approximately 50% for the full year, anticipating stronger growth in the second half.
Key Highlights
- Q1 2026 revenue decreased 10% to $47.2 million from $52.6 million in Q1 2025.
- Net loss for Q1 2026 was $(18.0) million, or $(0.28) per share, compared to $(15.9) million, or $(0.25) per share, in Q1 2025.
- Adjusted EBITDA was $(5.5) million in Q1 2026, compared to $(3.8) million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, up $3.5 million from December 31, 2025.
- Initiated limited market release of SuperBite Compression Screw System with successful first commercial cases.
- Broadened global patent portfolio surpassing 130 granted patents and over 200 pending applications.
- Reaffirmed full-year 2026 revenue guidance in the range of $202 million to $212 million, representing a decline of 5% to 0%.
- Reiterated expectation for full-year 2026 Adjusted EBITDA loss in the range of $4.0 million to $6.0 million.